We used established neuroblastoma cell lines with high, low, or heterogeneous antigen expression, and showed that the in vitro efficacy of L1CAM-directed CAR T cells was significantly reduced when the tumor antigen was less strongly or heterogeneously expressed on tumor cells. The gene discussed is L1CAM; the disease is neoplasm.